Ophiomics
↗Lisbon, Portugal
Ophiomics is a precision medicine biotechnology company based in Lisbon, Portugal, specializing in the development of bioinformatics and molecular diagnostic solutions for liver cancer. The company leverages machine learning and genomics to provide clinicians with decision-support tools that improve patient outcomes in oncology, specifically focusing on hepatocellular carcinoma (HCC).
Their flagship product, HepatoPredict, is a prognostic tool designed to identify which patients with liver cancer are most likely to benefit from a liver transplant. By analyzing specific genetic markers, Ophiomics aims to optimize the allocation of donor organs and reduce the risk of cancer recurrence post-transplant.
CLASSIFICATION
Company Type:Diagnostics
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Diagnostics & Precision Medicine
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$5M
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$5M
Investors:European Innovation Council (EIC), Portugal Ventures, Hovione Capital
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (CE-IVD)
Modalities:Molecular Diagnostics, Bioinformatics, Machine Learning, NGS
Active Trials:2
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Champalimaud Foundation, EIT Health, University of Lisbon, Hospital Curry Cabral
COMPETITION
Position:Emerging
Competitors:Exact Sciences, Glycotest, Cibiltech, Oncotype DX (Genomic Health), Grail
LEADERSHIP
Key Executives:
José Leal - CEO & Founder
Nuno Arantes-Oliveira - Chairman
Scientific Founders:José Leal
Board Members:Nuno Arantes-Oliveira, José Leal
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ophiomics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.